Scienture Holdings, Inc. (SCNX)
NASDAQ: SCNX · Real-Time Price · USD
1.410
-0.140 (-9.03%)
Mar 31, 2025, 1:08 PM EDT - Market open
Scienture Holdings Revenue
In the year 2024, Scienture Holdings had annual revenue of $136.64K, down -82.92%. Scienture Holdings had revenue of $53.08K in the quarter ending December 31, 2024, a decrease of -58.74%.
Revenue (ttm)
$136.64K
Revenue Growth
-89.98%
P/S Ratio
38.29
Revenue / Employee
$7,192
Employees
19
Market Cap
17.65M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 136.64K | -663.36K | -82.92% |
| Dec 31, 2023 | 800.00K | 500.00K | 166.67% |
| Dec 31, 2022 | 300.00K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionSCNX News
- 6 days ago - SCIENTURE Announces Commercial Operations Leadership and Strategic Agreement with Syneos Health, a leading Contract Sales Organization - GlobeNewsWire
- 12 days ago - Scienture Holdings Announces Draw on ELOC, Temporarily Suspends Further Draws Until Reaching $10/Share or 30 Trading Days - GlobeNewsWire
- 13 days ago - SCIENTURE announces the U.S. FDA Approval of its NDA for SCN-102, to be launched as ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL. The global market for losartan potassium was approximately $1.5 billion in sales in 2024. - GlobeNewsWire
- 25 days ago - SCIENTURE to commercially launch REZENOPY®, a life-saving opioid overdose emergency treatment through a collaboration with KINDEVA DRUG DELIVERY L.P. - GlobeNewsWire
- 2 months ago - Scienture Holdings, Inc. Announces Dr. Narasimhan Mani's Participation in the 8th Annual Conference of The Society for the Study of Xenobiotics - GlobeNewsWire
- 3 months ago - Scienture Holdings, Inc. Announces Participation in The Microcap Conference 2025 - GlobeNewsWire
- 3 months ago - Scienture, LLC, a wholly owned subsidiary of Scienture Holdings, Inc. (NASDAQ: SCNX) Announces Issuance of a New Patent Covering its first product SCN-102 (Losartan Potassium Oral Suspension, 10mg/mL) through 2041 - GlobeNewsWire
- 6 months ago - TRxADE Health, Inc. Announces Name Change to Scienture Holdings, Inc. and Ticker Symbol Change to “SCNX” - GlobeNewsWire